PL2425000T3 - Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami - Google Patents
Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusamiInfo
- Publication number
- PL2425000T3 PL2425000T3 PL10716723T PL10716723T PL2425000T3 PL 2425000 T3 PL2425000 T3 PL 2425000T3 PL 10716723 T PL10716723 T PL 10716723T PL 10716723 T PL10716723 T PL 10716723T PL 2425000 T3 PL2425000 T3 PL 2425000T3
- Authority
- PL
- Poland
- Prior art keywords
- adeno
- compositions
- associated virus
- airway cells
- virus constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17414909P | 2009-04-30 | 2009-04-30 | |
| PCT/US2010/032943 WO2010127097A1 (en) | 2009-04-30 | 2010-04-29 | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
| EP10716723.1A EP2425000B1 (en) | 2009-04-30 | 2010-04-29 | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2425000T3 true PL2425000T3 (pl) | 2019-08-30 |
Family
ID=42358394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10716723T PL2425000T3 (pl) | 2009-04-30 | 2010-04-29 | Kompozycje do kierowania komórek przewodzących do dróg oddechowych zawierające konstrukty wirusów związanych z adenowirusami |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10920244B2 (pl) |
| EP (1) | EP2425000B1 (pl) |
| JP (2) | JP6174318B2 (pl) |
| CN (1) | CN102439157B (pl) |
| DK (1) | DK2425000T3 (pl) |
| ES (1) | ES2724122T3 (pl) |
| HU (1) | HUE044522T2 (pl) |
| PL (1) | PL2425000T3 (pl) |
| TR (1) | TR201906398T4 (pl) |
| WO (1) | WO2010127097A1 (pl) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102439157B (zh) * | 2009-04-30 | 2015-09-16 | 宾夕法尼亚大学托管会 | 包含腺伴随病毒构建体的靶向传导气道细胞组合物 |
| WO2012112832A1 (en) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer |
| DE102013215817A1 (de) | 2013-08-09 | 2015-02-12 | Universitätsklinikum Hamburg-Eppendorf | Neue peptide mit spezifität für die lunge |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| DE102014207498A1 (de) | 2014-04-17 | 2015-10-22 | Universitätsklinikum Hamburg-Eppendorf | Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| PL3198018T3 (pl) * | 2014-09-24 | 2021-07-19 | City Of Hope | Warianty wektora wirusa związanego z adenowirusami dla wysokiej skuteczności edycji genomu i jego sposoby |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| CN107207556B (zh) | 2014-11-14 | 2020-12-08 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| KR102652994B1 (ko) | 2016-05-18 | 2024-04-01 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| EP3491008A2 (en) | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| EP3506817A4 (en) | 2016-08-30 | 2020-07-22 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| CN111108198A (zh) | 2017-05-05 | 2020-05-05 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| AU2018302016A1 (en) | 2017-07-17 | 2020-02-06 | The Regents Of The University Of California | Trajectory array guide system |
| WO2019067840A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | RESTRICTING CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE FROM FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION |
| CA3077426A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| BR112020015798A2 (pt) | 2018-02-01 | 2021-03-09 | Homology Medicines, Inc. | Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas |
| US11306329B2 (en) | 2018-02-19 | 2022-04-19 | City Of Hope | Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof |
| WO2019212922A1 (en) | 2018-04-29 | 2019-11-07 | Regenxbio Inc. | Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles |
| EP3787771A1 (en) | 2018-04-29 | 2021-03-10 | REGENXBIO Inc. | Scalable clarification process for recombinant aav production |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| CA3099306A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| EP3807404A1 (en) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
| IL279193B2 (en) | 2018-06-14 | 2025-07-01 | Regenxbio Inc | Anion exchange chromatography for recombinant AAV production |
| MX2021000810A (es) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Sistemas y metodos para producir formulaciones de terapia genetica. |
| US20210163991A1 (en) | 2018-08-10 | 2021-06-03 | Regenxbio Inc. | Scalable method for recombinant aav production |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| TW202035689A (zh) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | 測量病毒載體粒子的效價及強度之方法 |
| EP3861107A1 (en) | 2018-10-05 | 2021-08-11 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
| US20210324483A1 (en) | 2018-10-15 | 2021-10-21 | Regenxbio Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| CN113166754A (zh) * | 2018-10-16 | 2021-07-23 | 蓝色等位基因有限责任公司 | 用于将dna靶向插入基因中的方法 |
| TW202102526A (zh) | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
| DK3953483T3 (da) | 2019-04-11 | 2023-12-18 | Regenxbio Inc | Fremgangsmåder til størrelseskromatografi til karakterisering af sammensætninger af rekombinant adeno-associeret virus |
| US20220143115A1 (en) | 2019-04-19 | 2022-05-12 | Regenxbio Inc. | Adeno-Associated Virus Vector Formulations and Methods |
| SG11202111414RA (en) | 2019-04-24 | 2021-11-29 | Regenxbio Inc | Fully-human post-translationally modified antibody therapeutics |
| EP3997225A1 (en) | 2019-07-10 | 2022-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
| US20230042103A1 (en) | 2019-07-26 | 2023-02-09 | Regenxbio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
| WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
| CA3159516A1 (en) | 2019-11-28 | 2021-06-03 | Chunping Qiao | Microdystrophin gene therapy constructs and uses thereof |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CA3177613A1 (en) | 2020-07-10 | 2022-04-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
| EP4213890A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized lanadelumab and administration thereof |
| EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
| WO2022076750A2 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| EP4225777A2 (en) | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Adeno-associated viruses for ocular delivery of gene therapy |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| TW202233841A (zh) | 2020-10-28 | 2022-09-01 | 美商銳進科斯生物股份有限公司 | 用於眼適應症之載體化抗ＴＮＦ－α抗體 |
| CN116457373A (zh) | 2020-10-29 | 2023-07-18 | 再生生物股份有限公司 | 用于眼部适应症的载体化TNF-α拮抗剂 |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| EP4244209A1 (en) | 2020-11-11 | 2023-09-20 | European Molecular Biology Laboratory | Modified viral particles for gene therapy |
| KR20230120128A (ko) | 2020-12-16 | 2023-08-16 | 리젠엑스바이오 인크. | 재조합 바이러스 입자의 생산 방법 |
| EP4271479A1 (en) | 2020-12-29 | 2023-11-08 | RegenxBio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
| WO2022159662A1 (en) | 2021-01-21 | 2022-07-28 | Regenxbio Inc. | Improved production of recombinant polypeptides and viruses |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| WO2022232141A1 (en) | 2021-04-26 | 2022-11-03 | Regenxbio Inc. | Microdystrophin gene therapy administration for treatment of dystrophinopathies |
| US20240218397A1 (en) | 2021-05-04 | 2024-07-04 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| US20240358857A1 (en) | 2021-05-11 | 2024-10-31 | Regenxbio Inc. | Treatment of duchenne muscular dystrophy and combinations thereof |
| CA3226452A1 (en) | 2021-07-19 | 2023-01-26 | New York University | Auf1 combination therapies for treatment of muscle degenerative disease |
| CN118202060A (zh) | 2021-10-05 | 2024-06-14 | 再生生物股份有限公司 | 用于重组aav生产的组合物和方法 |
| WO2023060113A1 (en) | 2021-10-05 | 2023-04-13 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| US20250179518A1 (en) | 2021-10-07 | 2025-06-05 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| WO2023060269A1 (en) | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for targeted delivery |
| EP4423285A1 (en) | 2021-10-28 | 2024-09-04 | RegenxBio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| EP4493226A1 (en) | 2022-03-13 | 2025-01-22 | RegenxBio Inc. | Modified muscle-specific promoters |
| US20250213727A1 (en) | 2022-03-25 | 2025-07-03 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| WO2023201277A1 (en) | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| EP4518972A2 (en) | 2022-05-03 | 2025-03-12 | RegenxBio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| US20250288697A1 (en) | 2022-05-03 | 2025-09-18 | Regenxbio Inc. | Vectorized anti-tnf-alpha inhibitors for ocular indications |
| WO2023239627A2 (en) | 2022-06-08 | 2023-12-14 | Regenxbio Inc. | Methods for recombinant aav production |
| WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
| JP2025527658A (ja) | 2022-08-24 | 2025-08-22 | リジェネックスバイオ インコーポレイテッド | 組換えアデノ随伴ウイルス及びその使用 |
| EP4601710A2 (en) | 2022-10-11 | 2025-08-20 | RegenxBio Inc. | Engineered nucleic acid regulatory elements and methods and uses thereof |
| EP4646478A1 (en) | 2023-01-06 | 2025-11-12 | Institut National de la Santé et de la Recherche Médicale | Intravenous administration of antisense oligonucleotides for the treatment of pain |
| EP4680741A2 (en) | 2023-03-15 | 2026-01-21 | RegenxBio Inc. | Exon skipping gene therapy constructs, vectors and uses thereof |
| EP4689137A1 (en) | 2023-04-07 | 2026-02-11 | REGENXBIO Inc. | Compositions and methods for recombinant aav production |
| EP4694904A2 (en) | 2023-04-13 | 2026-02-18 | REGENXBIO Inc. | Targeting aav capsids, methods of manufacturing and using same |
| WO2024233529A2 (en) | 2023-05-07 | 2024-11-14 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2024238853A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Adeno-associated viruses for ocular delivery of gene therapy |
| WO2024238859A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
| AU2024271004A1 (en) | 2023-05-16 | 2026-01-15 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| WO2025008406A1 (en) | 2023-07-04 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of cancer |
| WO2025090962A1 (en) | 2023-10-25 | 2025-05-01 | Regenxbio Inc. | Compositions and methods for recombinant aav production |
| WO2025106374A1 (en) | 2023-11-13 | 2025-05-22 | Juno Therapeutics, Inc. | Aav production method |
| WO2025108407A2 (en) | 2023-11-23 | 2025-05-30 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Gene therapy compositions and methods for treating glioma |
| WO2025113676A1 (en) | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2025217214A2 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Recombinant adeno-associated viruses and uses thereof |
| WO2025237990A1 (en) | 2024-05-14 | 2025-11-20 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis |
| WO2026006341A1 (en) | 2024-06-24 | 2026-01-02 | Regenxbio Inc. | Microdystrophin gene therapy administration for treatment of dystrophinopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| JP2006075171A (ja) * | 1995-11-09 | 2006-03-23 | Avigen Inc | 組換えａａｖビリオン産生における使用のための補助機能 |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| AU780231B2 (en) * | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| SG10201506627PA (en) | 2001-11-13 | 2015-10-29 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| WO2005017101A2 (en) * | 2003-05-19 | 2005-02-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH | Avian adenoassociated virus (aaav) and uses thereof |
| CN102212558B (zh) | 2003-09-30 | 2016-08-03 | 宾夕法尼亚大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| CN101203613B (zh) * | 2005-04-07 | 2012-12-12 | 宾夕法尼亚大学托管会 | 增强腺相关病毒载体功能的方法 |
| US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
| US8632764B2 (en) * | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| WO2010109874A1 (ja) | 2009-03-26 | 2010-09-30 | 国立大学法人東京海洋大学 | コイヘルペスウイルス特異的抗体及びその抗原 |
| CN102439157B (zh) | 2009-04-30 | 2015-09-16 | 宾夕法尼亚大学托管会 | 包含腺伴随病毒构建体的靶向传导气道细胞组合物 |
-
2010
- 2010-04-29 CN CN201080019389.4A patent/CN102439157B/zh not_active Expired - Fee Related
- 2010-04-29 HU HUE10716723 patent/HUE044522T2/hu unknown
- 2010-04-29 TR TR2019/06398T patent/TR201906398T4/tr unknown
- 2010-04-29 DK DK10716723.1T patent/DK2425000T3/da active
- 2010-04-29 ES ES10716723T patent/ES2724122T3/es active Active
- 2010-04-29 JP JP2012508722A patent/JP6174318B2/ja not_active Expired - Fee Related
- 2010-04-29 EP EP10716723.1A patent/EP2425000B1/en active Active
- 2010-04-29 PL PL10716723T patent/PL2425000T3/pl unknown
- 2010-04-29 WO PCT/US2010/032943 patent/WO2010127097A1/en not_active Ceased
- 2010-04-29 US US13/266,599 patent/US10920244B2/en not_active Expired - Fee Related
-
2017
- 2017-03-17 JP JP2017052379A patent/JP2017127316A/ja active Pending
-
2021
- 2021-01-14 US US17/149,025 patent/US20210147875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2425000T3 (da) | 2019-05-13 |
| TR201906398T4 (tr) | 2019-05-21 |
| US20120046349A1 (en) | 2012-02-23 |
| EP2425000B1 (en) | 2019-02-20 |
| JP2017127316A (ja) | 2017-07-27 |
| HUE044522T2 (hu) | 2019-10-28 |
| US20210147875A1 (en) | 2021-05-20 |
| JP2012525150A (ja) | 2012-10-22 |
| ES2724122T3 (es) | 2019-09-06 |
| CN102439157B (zh) | 2015-09-16 |
| WO2010127097A1 (en) | 2010-11-04 |
| CN102439157A (zh) | 2012-05-02 |
| EP2425000A1 (en) | 2012-03-07 |
| JP6174318B2 (ja) | 2017-08-02 |
| US10920244B2 (en) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE044522T2 (hu) | Adeno-asszociált vírus konstrukciókat tartalmazó légúti vezetõ sejtek célzására szolgáló kompozíciók | |
| SG10201507749UA (en) | Fuel compositions comprising isoprene derivatives | |
| GB201003973D0 (en) | Fuel compositions | |
| ZA201106050B (en) | Dye-polymers formulations | |
| EP2651958A4 (en) | Glycoside blends | |
| GB2477038B (en) | Toner compositions | |
| IL225415A0 (en) | Electrolytic formulations | |
| GB201119596D0 (en) | Improved compositions | |
| IL269369A (en) | The vehicles are improved | |
| EP2531167A4 (en) | COMPOSITIONS FOR TARGETING HAIRFOLLICLES | |
| GB0919210D0 (en) | Formulations | |
| SG10201706265PA (en) | Novel compounds and compositions for targeting cancer stem cells | |
| IL216351A0 (en) | Casb7439 constructs | |
| ZA201208412B (en) | Composition comprising cinnamon | |
| GB2475786B (en) | Fuel formulations | |
| EP2558506A4 (en) | GEWEBEANZIELUNG | |
| EP2398462A4 (en) | PH-MODULATED FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| EP2421952A4 (en) | COMPOSITIONS FOR THE TRANSFECTION OF BIOMOLECULES IN CELLS | |
| GB2482236B (en) | Toner compositions | |
| ZA201102764B (en) | Composition for targeting dendritic cells | |
| GB2477040B (en) | Toner compositions | |
| GB201019966D0 (en) | Fuel formulations | |
| GB201019953D0 (en) | Fuel formulations | |
| GB201003203D0 (en) | Biodiesel compositions | |
| GB0903164D0 (en) | Fuel compositions |